Pharmacokinetics and pharmacodynamics of a new beclomethasone dipropionate and formoterol CFC-free fixed combination in healthy volunteers Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006
PK and PD of a new beclomethasone dipropionate and formoterol CFC-free fixed combination Source: Eur Respir J 2007; 30: Suppl. 51, 358s Year: 2007
Systemic effects and pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients Source: Eur Respir J 2005; 26: Suppl. 49, 180s Year: 2005
Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler® Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Long-term benefits of switching to hydrofluoroalkane beclomethasone dipropionate extrafine aerosol Source: Eur Respir J 2001; 18: Suppl. 33, 331s Year: 2001
Does Clickhaler match the Turbuhaler for efficacy of inhaled budesonide? Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Systemic activity of beclometasone dipropionate HFA and CFC formulations in metered dose inhalers assessed by knemometry Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Dose linearity of beclometasone dipropionate (BDP) in a pMDI BDP plus formoterol fixed combination Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Comparative clinical study of addition theophylline to low-dose inhaled beclomethasone dipropionate and medium-dose inhaled beclomethasone dipropionate in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 98s Year: 2001
Dose-proportional lung bioavailability of beclometasone dipropionate and formoterol fumarate across three different dose strenghts of CHF1535 pMDI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler(R) Source: Eur Respir J 2001; 17: 1332-1333 Year: 2001
Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006
HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005
Comparison of mometasone furoate dry powder inhaler 400 mcg once daily in the evening with fluticasone propionate metered dose inhaler 250 mcg twice daily in asthma patients previously maintained on fluticasone propionate Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Evaluation of the systemic pharmacodynamic effects of two HFA formulations of Salmeterol xinafoate/Fluticasone propionate HFA pMDI 25/250 mcg Source: International Congress 2017 – Inhalers and their use Year: 2017
Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002